Researchers are reporting promising results for people with mesothelioma who can have surgery. One researcher tested immunotherapy before and after surgery while the other researcher studied a blood test that helps doctors detect mesothelioma earlier than scans. Doctors at several cancer centers, including Johns Hopkins, ran an early clinical trial[…]
From the blog
Cell Mutations and Peritoneal Mesothelioma
Peritoneal mesothelioma is a hard cancer to treat because it is very aggressive and rare. It is usually found late due to it being rare and having unclear symptoms, making treatment very difficult. Current treatments that can include surgery and chemotherapy have limited success against the cancer. New ways to[…]
New Biomarkers for Diagnosing Mesothelioma
Mesothelioma is a rare cancer linked to asbestos exposure that is dangerous for elderly Americans. It is hard to tell the difference between reactive and cancerous cells. This could be changed though due to a study in the American Journal of Pathology. The study identifies a key biomarker, ACADL, using[…]
Palliative Care for Mesothelioma Symptoms
Palliative care is crucial in improving quality of life for people with life threatening diseases like mesothelioma. Understanding the spectrum of diseases that patients experience is important for providing effective care. Palliative care is a medical specialty that focuses on easing pain and other life limiting symptoms. Palliative care is[…]
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
Primary Outcome Measures Disease-related Symptom Burden 3 Months After Partial Pleurectomy (Surgery) Secondary Outcome Measures Quality of Life of Study Participants Who Have Undergone Partial Pleurectomy (Surgery) Rate of Complications after Partial Pleurectomy (Surgery) Time to Resumption of Systemic Therapy Overall Survival of Study Participants Who Have Undergone Partial Pleurectomy[…]
Mesothelioma Diagnosis
Mesothelioma is a rare and hard to diagnose cancer. There are many challenges patients and caregivers must face once someone is diagnosed with mesothelioma. There are expert guidelines that were recently updated by the International Mesothelioma Interest group. The group provides insights into mesothelioma’s diagnosis, which is incredibly valuable for[…]
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
Primary Outcome Measures ORR Inclusion Criteria Subjects must provide informed consent prior to initiating any study-specific procedures. Male or female subjects aged ≥18 and ≤75 years. Histologically/cytologically confirmed malignant mesothelioma (MM), including malignant pleural mesothelioma (PM) and malignant peritoneal mesothelioma (PeM). Subjects with MM unsuitable for radical resection and/or radiotherapy[…]
Empyema Challenges After Pleural Mesothelioma Surgery
Pleural mesothelioma, a cancer linked to asbestos exposure, is very tough to treat. Surgery is one part of multimodal therapy that aims to remove as much cancer as possible. Surgery is a very useful tool in the treatment of mesothelioma, but after surgery, complications can occur. One complication can be[…]
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study (NECIM)
Primary Outcome Measures To assess the percentage of successful completion of a neoadjuvant double chemotherapy / double immunotherapy regimen followed by surgery in a selected group of T2-T3 (according to TNM 9) patients with pleural mesothelioma. Secondary Outcome Measures Toxicity of the neoadjuvant double chemotherapy / double immunotherapy regimen and[…]
Advances in Immunotherapy for Mesothelioma
Malignant mesothelioma is a very rare cancer that often has a poor outlook in cancer treatment. Immunotherapy, especially in the form of immune checkpoint inhibitors, has brought hope. It shows the potential for better outcomes in mesothelioma patients. A new article in Open Respiratory Archives provides a history of recent[…]
Skip to content